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The present investigation deals with molecular docking, synthesis, characterization, and evaluation of in vitro tyrosine 
kinase inhibitor activity of a series of 4-[2-(substituted phenyl) hydrazono]-3-(1-hydroxyethyl)-1-phenyl/methyl- 
3,4-dihydroquinolin-2(1H)-one derivatives {III-a(1-12)/III-b(1-12)}. Molecular docking studies of the title compounds were 
carried out using Molegro Virtual Docker (MVD-2013, 6.0) software. The MolDock scores of the derivatives ranged from 
(−66.508) to (−101.274); whereas the MolDock score of standard 4-anilinoquinazoline ligand was found to be (−105.219). Most 
of the synthesized qunolin-2-one derivatives showed better affinity towards EGFRK protein as compared to standard drug 
imatinib (−104.253). All the synthesized compounds were satisfactorily characterized by physical and spectral analysis (UV, IR, 
1H NMR and 13C NMR and mass spectral data). Twelve derivatives were tested for their in vitro tyrosine kinase inhibitor 
activity using MDA-MB cell line. Compound 4-[2-(4-bromophenyl)hydrazono]-3-(1-hydroxyethyl)-1- methyl- 
3,4-dihydroquinolin-2(1H)-one (III-b4) was found to be the most cytotoxic compound as compared to other synthesized 
derivatives, with IC50 value of 0.0515 μM against MDA- MB cell line. 
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Cancer is the second leading cause of death after heart 
disease in men, but is the leading cause of death in 
women of every age group1. Cancer is responsible for 
an estimated 9.6 million deaths in 20182. Globally, 
about one in six deaths is due to cancer2. Around 1.7 
million new cases i.e. around 4600 cases per day were 
projected for the year 20191. Although current use of 
chemotherapeutic agents has resulted in reduction of 
mortality and morbidity among the cancer patients; the 
major drawback of these anticancer drugs is its high 
toxicity and non-specific targeting3. These drawbacks 
along with drug resistance are a major challenge in the 
treatment of this disease thus; discovery of target 
selective anticancer agents is the need of the hour3. 
The quinolin-2-one structure is characteristic of a 
number of natural products and synthetic analogues. 
Clinically used quinolone derivatives have a wide 
therapeutic importance such as carteolol with β-blocker 
(used in ophthalmic preparations), camptothecin with 
antitumor, vesnarinone with cardiotonic, rebapimide 
with antiulcer and antioxidant, aripiprazole with 
antipshychotic, and brexpipriprazole with 
antidepressant activity4-6. Quinolones are amongst the 
most popular N-heteroaromatic compounds and are of 
considerable interest clinically since their discovery. 
Research on 2-quinolone, led to a discovery of 
4-hydroxyquinolin-2(1H)-ones which was found to be
a fundamental ring system of a large number of
alkaloids of Rutaceae family7. 3-Substituted-4-hydroxy
quinolin-2-one is an important moiety which was
found in a number of compounds with interesting
antitumor activity. This structural key feature
encouraged and attracted the interest of several
research groups.
One of the clinically important analogues of 
quinolin-2-one derivatives is Linomide8,9. Linomide, 
IUPAC name (4-hydroxy-N, 1-dimethyl-2-oxo-N-
phenyl-1, 2-dihydroquinolin-3- carboxamide), a 
synthetic immunomodulator (withdrawn from III-
stage of clinical trials), protects animals against a 
variety of experimental autoimmune diseases. The 
structure of linomide has served as the prototype for 
the synthesis of a variety of analogues in an effort to 
optimise this lead compound. In present study, the 




carbonyl group present at the acetyl side chain of the 
3rd position of 3-acetyl-4-hydroxy-1-phenyl/methyl 
quinolin-2(1H)-one was reduced to an (±)-4-hydroxy-
3-(1-hydroxyethyl)-phenyel/methylquinolin-2(1H)-one. 
The purpose of reduction of carbonyl group to its 
hydroxyl derivative was to avoid interference of the 
former group in the reaction with the substituted 
phenylhydrazines. 
 
Results and Discussion 
The starting material, 3-acetyl-4-hydroxy-1-
phenyl/methylquinolin-2(1H)-one [Ia/Ib] was synthesized 
following the literature10. Reduction of compound [I-a/I-
b] using sodium borohydrate gave 4-hydroxy-3-(1-
hydroxyethyl)-1phenyl/methyl quinolin-2(1H)-one [II-
a/II-b]. Further treatment on [II-a/II-b] with substituted 
aromatic phenylhydrazines with acetic anhydride gave 
4-[2-(substituted phenyl)hydrazono]-3-(1-hydroxyethyl)-
1-phenyl/methyl-3,4-dihydroquinolin-2(1H)-one[III-
a(1-12)/III-b(1-12)] (Scheme I). 
The physical data of all synthesized compounds is 
given in Table I and Table II. All the synthesized 
compounds were characterized by physical and spectral 
analysis. The in vitro tyrosine kinase inhibitor activity 
of twelve derivatives was performed by MTT assay on 
MDA- MB cell line. Compound 4-[2-(4-
bromophenyl)hydrazono]-3-(1-hydroxyethyl)-1-methyl-
3,4- dihydroquinolin-2(1H)-one (III-b4) was found to 
be the most cytotoxic as compared to other 
derivatives with IC50 value of 0.0515 μM. Compounds 
(III-a2), (III-a4) and (III-b2) had less potent activity 
with IC50 value of 0.0641 μM, 0.0555 μM, and 0.0764 
μM respectively. Compounds (III-a3), (III-a5),  
(III-a6) and (III-b1) which had an IC50 value of 
0.0756 μM, 0.0808 μM, 0.072 μM, and 0.0873 μM 
respectively also showed less potent activity. The 
least activity was seen in compounds (III-a1), (III-a7), 
(III-b3) and (III-b10) with IC50 value of 0.1232 μM, 
0.1297 μM, 0.1495 μM, and 0.1322 μM respectively. 
 
Molecular Docking studies 
Epidermal Growth Factor Receptor tyrosine kinase 
(EGFRK) was selected as the target enzyme for the 
designed molecules. Protein kinase inhibitors represent 
an important and still emerging class of targeted 
therapeutic agents. Drug discovery and development 
strategies have explored numerous approaches to target 
the inhibition of protein kinase signaling11. Tyrosine 
kinases are an especially important target because they 
play an important role in the modulation of growth 
factor signaling12. Tyrosine kinase inhibitors (TKIs) 
compete with the ATP binding site of the catalytic 
domain of several oncogenic tyrosine kinases12. TKIs 
such as imatinib mesylate, gefitinib, erlotinib, iapatinib, 
 
 
Scheme I — Synthesis of 4-[2-(substituted phenyl)hydrazono]-3-(1-hydroxyethyl)-1phenyl/methyl-3,4-dihydroquinolin-2(1H)-one 




etc. have a lot of clinical significance. First, in many 
tumor types they tend to stabilize tumor progression 
and may create a chronic disease state which is no 
longer immediately life threatening. Second, side 
effects are minimal when compared to conventional 
chemotherapeutic agents. Third, synergistic effects are 
seen in vitro when TKIs are combined with 
radiotherapy and/or conventional chemotherapeutic 
agents13. Molecular docking studies of the synthesized 
compounds were performed using Molegro Virtual 
Docker (MVD-2013, 6.0) software14. Following the 
literature, imatinib was used as the reference standard 
for docking12. Docking of the synthesized compounds 
on EGFR tyrosine kinase enzyme exhibited well-
conserved hydrogen bonds with one or more amino 
acid residues at the active binding site. The highest 
MolDock score exhibited by compound (III-a12) was 
(-101.274) comparable to that of the standard ligand  
4-anilinoquinazoline (-105.219) and imatinib  
(-104.259). Most of the synthesized novel analogues of 
quinolin-2-one exhibited better affinity towards 
EGFRK protein than imatinib12. The crystal structure 
of the target enzyme including forty amino acids from 
the carboxyl-terminal tail has been determined to 2.6-A 
resolution. Unlike any other kinase enzymes, the 
EGFR family members possess constitutive kinase 
activity without a phosphorylation event within their 
kinase domains. Despite its lack of phosphorylation, 
the EGFRK activation loop adopts a conformation 
similar to that of the phosphorylated active form of the 
kinase domain from the insulin receptor. It is observed 
that the key residues of a dimerised structure lying 
between the EGFRK domain and carboxyl-terminal 
substrate docking sites are found in close contact with 
the kinase domain11. 
The site at which the known 4-anilinoquinazoline 
inhibitor binds with the target protein was selected as 
the active site (Figure 1). It is lined with amino acid 
residues such as Met769, Thr830, Asp831, Lys721, 
Cys773, Pro770, Glu738, Gln767, etc. Hence to 
identify other residual interactions, a grid box (include 
residues within a 15.0 Å radius) large enough to 
Table I — Physical data of compounds 4-[2-(substituted phenyl) hydrazono]-3-(1-hydroxyethyl)-1-phenyl-3,4-dihydroquinolin-2 
(1H)-one {III-a(1-12)} 
Compd R R1 Mol. formula Mol. Wt. Yield (%) m.p. (°C) Rf value 
III-a1 -C6H5 -3Cl C23H20ClN3O2 405.88 88.51 72-4 0.78 
III-a2 -C6H5 -3F C23H20FN3O2 389.42 82.39 98-2 0.75 
III-a3 -C6H5 -4CN C24H20N4O2 396.44 80.31 76-9 0.78 
III-a4 -C6H5 -4Br C23H20BrN3O2 450.33 78.51 86-8 0.82 
III-a5 -C6H5 -H C23H21N3O2 371.43 90.21 110-2 0.81 
III-a6 -C6H5 -3NO2 C23H20N4O4 416.43 80.58 122-2 0.73 
III-a7 -C6H5 -2CH3 C24H23N3O2 385.46 71.09 161-3 0.69 
III-a8 -C6H5 -3CH3 C24H23N3O2 385.46 84.94 140-2 0.65 
III-a9 -C6H5 -4CH3 C24H23N3O2 385.46 91.78 180-4 0.90 
III-a10 -C6H5 -2,4-Cl C23H19Cl2N3O2 440.32 77.96 145-7 0.50 
III-a11 -C6H5 -2,4-CH3 C25H25N3O2 399.48 87.50 175-7 0.88 
III-a12 -C6H5 -2,4-NO2 C23H19N5O6 461.43 92.48 135-6 0.78 
 
Table II — Physical data of compounds 4-[2-(substituted phenyl) hydrazono]-3-(1-hydroxyethyl)-1-methyl-3,4-dihydroquinolin-2 
(1H)-one {III-b(1-12)} 
Compd R R1 Mol. formula Mol. Wt. Yield (%) m.p. (°C) Rf value 
III-b1 -CH3 -3Cl C18H18ClN3O2 343.81 95.45 138-9 0.79 
III-b2 -CH3 -3F C18H18FN3O2 327.35 93.68 136-8 0.87 
III-b3 -CH3 -4CN C19H18N4O2 334.37 88.52 140-4 0.77 
III-b4 -CH3 -4Br C18H18BrN3O2 388.26 80.94 133-4 0.83 
III-b5 -CH3 -H C18H19N3O2 309.36 75.47 132-5 0.77 
III-b6 -CH3 -3NO2 C18H18N4O4 354.36 78.98 120-6 0.87 
III-b7 -CH3 -2CH3 C19H21N3O2 323.39 70.32 110-8 0.79 
III-b8 -CH3 -3CH3 C19H21N3O2 323.39 82.45 1424 0.75 
III-b9 -CH3 -4CH3 C19H21N3O2 323.39 90.18 146-7 0.71 
III-b10 -CH3 -2,4-Cl C18H17Cl2N3O2 378.25 76.29 174-8 0.50 
III-b11 -CH3 -2,4-CH3 C20H23N3O2 337.18 93.15 196-8 0.90 
III-b12 -CH3 -2,4-NO2 C18H17N5O6 399.36 82.53 182-4 0.88 
 




accommodate the active site was constructed. Since 4-
anilinoquinazoline is a known inhibitor, the centre of 
the binding site of this ligand was considered as the 
centre of search space for docking. The MolDock 
scores of the derivatives ranged from (−66.508) to  
(− 101.274); whereas the MolDock score of standard 
4-anilinoquinazoline ligand was found to be 
(−105.219). Imatinib was used as the reference 
standard which exhibited MolDocK score of 
(−104.253). The docking results of the best poses of 
compounds are summarised in Table III. 
 
Experimental Section 
The reagents and chemicals were purchased from SD 
Fine-Chem Limited, Mumbai and Molychem, Mumbai. 
Melting points of synthesized compounds were 
determined by Thiel’s melting point apparatus and are 
uncorrected. λmax was recorded on UV-1800 Shimadzu 
UV Spectrophotometer. FT-IR spectra were recorded on 
Shimadzu IR AFFINITY-1 spectrophotometer by using 
KBr pellets. The1H and 13C NMR was recorded on 
Bruker Advance II 400 NMR Spectrometer by using 
CDCl3 or DMSO-d6 as solvent and TMS as internal 
standard, chemical shifts are expressed as δ values 
(ppm). The Mass spectra were recorded on Waters,  
Q-TOF Micromass (LC-MS). 
 
General procedure for the synthesis of 3-(1-
hydroxyethyl)-4-hydroxy-1-phenyl/methyl- quinolin-
2(1H)-one {II-a/II-b} 
The suspension of the 3-substituted-4-
hydroxyquinolin-2-one Ia/Ib (1mmole) in methanol 
(5 mL) was cooled to 0°C, a solution of sodium 
borohydride (3.7 mmol) in ethanol was added dropwise 
 
 
Figure 1 — (a) Structure of EGFR-tyrosine kinase domain complexed with 4- anilinoquinazoline inhibitor (PDB ID: 1m17); (b) Ligand 
4-anilinoquinazoline docked in its best conformation into the binding site of 1m17. The –NH at 1st of the quinazoline moiety shows 
hydrogen bonding interaction with oxygen of Met 769; (c) Imatinib docked in best of its conformation into the binding site of 1m17. One
of the –NH of the pyrimidine ring system forms one hydrogen bond with the oxygen of Gln 767. The –N at the amino linkage between 
pyrimidine and o-methyl substituted phenyl ring system forms hydrogen bond with oxygen of Met 769. The oxygen of the peptide
linkage forms two hydrogen bonds with –SH and –NH of Cys 773; (d) Compound 4-[2-(4-bromo-phenyl)hydrazono]-3-(1-hydroxyethyl)-
1-methyl-3,4- dihydroquinolin-2(1H)-one (III-b4) (III-b4): The –N at 1st position of the quinolone moiety forms hydrogen bond with –OH 
of Thr 830. The oxygen at 2nd position of the quinolone moiety forms hydrogen bond with –NH of Lys 721. The –OH at the side chain 
(at position 3) of the quiolin-2-one moiety forms hydrogen bond with –O of Asp 831. 
 




till the suspension becomes a clear solution. To the clear 
solution, a mixture of n-hexane and diethyl ether  
(1:1, 15 mL) was added. The solvents were removed by 
using rota evaporator (IKA make) and the residue was 
dried and purified by column chromatography on silica 
gel eluting with hexane and ethyl acetate 5:1and 
recrystallized from methanol. 
 
Spectral data of the compounds 
 
4-Hydroxy-3-(1-hydroxyethyl)-1-phenylquinolin-
2(1H)-one II-a: UV-Vis: λmax = 234 nm; IR (KBr): 
3469.94 (-OH); 3062.96 (aromatic -C-H); 2918.30 
cm−1 (aliphatic-C-H str.); 1597.06 (-C=O amide); 
1H NMR (DMSO-d6): δ 17.1 (s, 1H, -OH); 8.2-6.4 (m, 
9H, ArH); 3.9 (t, 1H, -CHOH); 3.3 (s, 1H, -OH of 
CHOH); 2.6 (s, 3H, -CH3). 
 
4-Hydroxy-3-(1-hydroxyethyl)-1-methylquinolin-
2(1H)-one II-b: UV-Vis: λmax = 231.70 nm; IR (KBr): 
3469.4 (-OH); 3062.96 (aromatic -C-H); 2613.5 
(aliphatic -C-H str.); 1691.57 cm−1 (-C=O amide); 
1H NMR (CDCl3): δ 16.79 (s, 1H, -OH); 8.1-7.0 (m, 
4H, ArH); 3.75(t, 1H, -CHOH); 3.72(s, 3H, -N-CH3); 
3.5 (s, 1H, -OH of CHOH); 2.7 (s, 3H, CH3). 
 




To a solution of II-a/ II-b (3mmoles), substituted 
phenylhydrazine (3.6 mmoles) and acetic anhydride 
(0.5 mL) in methanol (25 mL) was refluxed for 12-14 
hours. The solvent was removed under reduced 
pressure using rotaevaporator (IKA make). The 
resulting solid was washed with cold water and 
recrystallized using methanol. The purity of all the 
newly synthesized compounds was ascertained by 
TLC using ethyl acetate: benzene in the ratio 1:3 as 
the mobile phase, silica gel G as stationary phase and 
iodine vapours as visualizing agent. 
 




a1): UV-Vis: λmax = 288.20 nm IR (KBr): 3460.3  
(-OH); 3292.49 (-NH); 3064.89 (aromatic C-H); 
3010.88 (aliphatic-C-H str.); 1658.78 (-C=N); 1595.13 
(-C=O amide); 773.46 cm−1 (CCl); 1H NMR (DMSO- 
d6): δ 9.6 (s, 1H, N-H); 8.0-6.5 (m, 13H, ArH); 3.4 
(quintet, 1H, - CHOH); 3.19 (s, 1H, OH of CHOH); 
2.5 (d, 1H, -CH aliphatic); 1.9 (d, 3H, -CH3); 
13C NMR (CDCl3): δ 169.20 (1C, C=O amide); 150.73 
(1C,C=N); 133.59-110.61(18C, aromatic carbon); 61.46 
(1C, CHOH); 52.20 (1C, CH aliphatic); 20.46 (1C, 





b1): UV-Vis: λmax = 316 nm; IR (KBr): 3620.39 
(-OH); 3290.56(-NH); 3010.88, 2926.01(aromatic -C-
H); 2378.23, 2316.51 (aliphatic-C-H str.); 1658.78  
(-C=N); 1595.13 (-C=O amide); 771.53 cm−1 (C-Cl); 
1H NMR (DMSO-d6): δ 9.6 (s, 1H, N-H); 8.9- 6.6 (m, 
8H, ArH); 3.7-3.6 (quintet, 1H, CHOH); 3.5(s, 1H, 
OH of CHOH); 3.2 (s, 3H, N-CH3); 2.5 (d, 1H, -CH 
aliphatic); 1.9 (d, 3H, - CH3); 13C NMR (CDCl3);  
δ 169.15 (1C, C=O amide); 150.75(1C, C=N); 
133.58-110.61(12C, aromatic carbon); 60.0(1C, 
CHOH); 50.6 (1C, CH aliphatic); 36.1 (1C, N-CH3); 




The selected 4-[2-(substituted phenyl) hydrazono]-
3-(1-hydroxyethyl)-1-phenyl/methyl-3,4-dihydroquin-
Table III — Docking results of of 4-[2-(substituted phenyl) hydrazono]-3-(1-hydroxyethyl)-1-phenyl/methyl-3,4-dihydroquinolin-2 
(1H)-one derivatives 
Compd MolDock Score Rerank Score H-Bond Compd MolDock Score Rerank Score H-bond 
III-a1 −88.7932 −71.2242 −2.5 III-b2 −85.2209 −17.0946 −5.98031 
III-a2 −88.8587 −71.0985 −2.5 III-b3 −79.4644 −59.391 −2.86824 
III-a3 −86.4336 −13.6673 −4.84744 III-b4 −78.2007 −68.6968 −4.29864 
III-a4 −85.6434 −69.9135 −2.5 III-b5 −70.1892 −63.2473 −2.5 
III-a5 −66.5082 6.05593 −2.5 III-b6 −73.8145 −10.4383 −7.69484 
III-a6 −97.2011 −78.3445 −8.71635 III-b7 −75.4982 −66.4725 −4.48108 
III-a7 −91.711 −74.3248 −2.5 III-b8 −67.133 −39.3542 −3.51184 
III-a8 −88.8456 −71.9322 −2.5 III-b9 −81.1738 −70.3943 −4.30778 
III-a9 −87.1244 −71.0905 −2.5 III-b10 −78.5617 −65.4074 −2.40001 
III-a10 −97.0357 −75.4252 −2.5 III-b11 −84.9681 −72.7725 −4.0689 
III-a11 −95.424 −76.4441 −2.5 III-b12 −92.7837 −73.0288 −8.56848 
III-a12 −101.274 −78.1923 −9.7562 Imatinib −104.253 −37.0559 −3.55828 
III-b1 −77.536 −67.8361 −3.16219 4-Anilinoquinazoline (Active Ligand) −105.219 −67.2192 −6.53953 
 




olin-2(1H)-one derivatives were tested for their 
in vitro tyrosine kinase inhibitor activity against 




bromide] (MTT) Assay: MTT solution preparation 
(stock solution): 5 mg in 1 mL of phosphate 
buffered saline (PBS). (pH- 7.4). 
(ii) In vitro growth inhibition effect of test compound 
was assessed by colorimetric or spectrophotometric 
determination of conversion of MTT into 
“Formazan blue” by living cells. 
 
50 μL of 1×105 cells/mL cell suspension was seeded 
into each well in a 96 well micro titer plate and final 
volume was made upto 150 μL by adding Dolbecco’s 
Modified Eagle’s Medium (DMEM) media. 100 μL of 
test compounds of different concentrations (10, 20, 25, 
30 and 50 μg/mL) was added to the wells and incubated 
for 24 hours, in presence of 5% CO2, at 37°C into CO2 
incubator. After 24 hours, 20 μL of 5 mg/mL MTT 
reagent was added to the wells. The plate was kept for 4 
hours incubation in dark place at room temperature. The 
plate was covered with aluminium foil, since MTT 
reagent is photosensitive. The supernatant was carefully 
removed without disturbing the precipitated Formazan 
crystals and 100 μL of DMSO was added to dissolve the 
crystals formed. The optical density (OD) was measured 
at wavelength of 570 nm. The study was performed in 
triplets and the result represents the mean of three 
readings using the following formula: 
Surviving cells (%) = (Mean OD of test 
compound/Mean OD at control) × 100 Inhibiting cells 
(%) = 100-Surviving cells 
The cell viability of the title compounds are given in 
Table IV and IC50 values of the tested compounds are 
given in Table V. 
All the compounds tested, showed potent tyrosine 
kinase inhibitor activity at different concentrations. 
 
Conclusion 
The in vitro tyrosine kinase inhibitor activity of 
twelve selected compounds was carried out against 
MDA-MB cell line based upon MTT assay method. 
From the results obtained, all the selected compounds 
showed activity compared to the control. The active 
compound III-b4 showed three interactions with amino 
acids Thr830, Lys 721, Asp 831 residues of the protein 
EGFR tyrosine kinase and the compound was most 
potent with an IC50 value of 0.0515μM. However, it did 
not show good MolDock score compared to the standard 
interaction of imatinib. 
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Table IV — Cell viability(%) of synthesized compounds on MDA-MB (Human mammary gland) cell line 
Conc (μg/mL) III-a1 III-a2 III-a3 III-a4 III-a5 III-a6 III-a7 III-b1 III-b2 III-b3 III-b4 III-b10 
10 70.53 55.2 63.59 53.12 70.22 59.24 60 68.52 58.42 63.28 72.30 71.36 
20 65.8 51.36 62.27 50.98 60.95 57.29 58.86 68.01 55.58 59.24 49.46 69.53 
25 62.4 49.21 57.85 49.78 50.98 51.48 57.85 58.42 43.15 58.3 48.14 59.24 
30 56.97 43.15 49.59 49.15 38.11 46.69 56.53 43.79 41.45 52.37 42.59 53.63 
50 42.71 29.65 40.76 41.32 37.79 41.51 49.9 42.78 39.87 44.92 37.48 41.77 
Control 100 100 100 100 100 100 100 100 100 100 100 100 
 
Table V — IC50 values of all the tested compounds 
Compd III-a1 III-a2 III-a3 III-a4 III-a5 III-a6 III-a7 III-b1 III-b2 III-b3 III-b4 III-b10 
IC50 (μM/mL) 0.123  0.064  0.076  0.056  0.081  0.072  0.13 0.087  0.076  0.15 0.052  0.132  
 
